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Abstract
Background: Stopping antipsychotic treatment can interrupt improvement and exacerbate the
illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to
explore this phenomenon.
Methods: A post-hoc, pooled analysis was made of 4 randomized, double-blind clinical trials, 24–
28 weeks in duration, involving 1627 patients with schizophrenia or a related disorder. Analyses
combined all the atypical antipsychotic treatment groups in the studies.
Results: The majority of patients (53%) stopped their treatment at an early stage. Poor psychiatric
response along with worsening symptoms was the most frequently given reason for discontinuing
the course (36%), which was substantially more common than discontinuation due to poor
tolerability of the medication (12%). This phenomenon was corroborated by less improvement in
patients who discontinued treatment compared with those who completed, based on the PANSS
total scores. Discontinuation due to poor response was, apparently, more predominantly linked to
patient perception than to physicians' conclusions alone (80% vs. 20%). Discontinuation due to
patient perception of poor response appeared to occur particularly early in the course of
treatment. Patients who discontinued due to poor toleration of the medication responded in a
more comparable manner with completers.
Conclusion:  Discontinuing treatment may lead to exacerbation of symptoms, undermining
therapeutic progress. In these studies, poor response to treatment and worsening of underlying
psychiatric symptoms, and to a lesser extent, intolerability to medication were the primary
contributors to treatment being discontinued. Our findings suggest that adherence may be
enhanced by effective symptom control, as objectively measured and as subjectively perceived.
Such strategies may improve patients' willingness to undertake long-term therapy and increase the
likelihood of a better prognosis.
Background
Adherence to a drug regime is a significant issue in the
clinical management of schizophrenia. Early treatment
discontinuation on the part of patients with schizophre-
nia or schizophrenia-like disorders is strikingly common,
with estimates of its prevalence in antipsychotic drug trials
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ranging from 25%–75%. The rates of nonadherence
appear to be even higher in natural, uncontrolled settings
[1-4]. The consequences of early termination of the treat-
ment are significant, making adherence to medication a
critical determinant of a generally good prognosis. Dis-
continuing a prescribed antipsychotic drug is associated
with symptom exacerbation [5], relapse [5,6], increased
hospitalization [5,6], poor long-term course of illness [7],
and higher economic costs of treatment [8]. Seventy-five
per cent of patients who stop taking their antipsychotic
medication experience significant worsening of symp-
toms over the course of a year compared with only 25% of
those who consistently take their medication [5,6].
There are many factors associated with stopping treatment
at an early stage. These can be separated into causes, such
as:
• treatment-related reasons, e.g. inadequate response and
adverse events;
• patient-related reasons, e.g. insight and attitude;
• and environmental elements, e.g. family support and
transportation availability [5,9,10].
Adverse effects of treatment are one of the more fre-
quently cited reasons for noncompliance with antipsy-
chotic medication [5,9]. A patient's likelihood of adhering
to prescribed medication is a product of an implicit and
subjective assessment of the relative costs and benefits of
adherence in relation to personal goals and constraints
[3,9,11].
Recently, cessation of medication has been used as a
measure of ineffectiveness in the management of schizo-
phrenia [12-14]. The National Institute of Mental Health
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) schizophrenia trial was a large, randomized, con-
trolled trial that evaluated the effectiveness of atypical and
conventional antipsychotic medications in patients with
schizophrenia over an 18-month period [14]. Its primary
variable was the time taken to reach discontinuation of
medication, for any reason. In this context, treatment dis-
continuation reflects in different proportions both patient
and clinician views of efficacy and tolerability.
The significant impact of treatment adherence on clinical
outcome and the increasing belief that continuation is as
a proxy for overall effectiveness make it important for us
to understand the reasons why treatment is in many cases
discontinued. Randomized, controlled clinical trials may
provide information that may help to shed light on what
happens under clinical care. We, therefore, undertook a
secondary analysis of actively-controlled trials of olanzap-
ine for schizophrenia and schizophrenia-like illnesses to
explore the reasons for treatment discontinuation by col-
lapsing all the treatment groups. Our goal was to better
understand the roles that efficacy and tolerability play in
treatment discontinuation, along with the relative roles of
patient and clinician perception.
Methods
Patient population
This was a post-hoc, pooled analysis of clinical trials
within the Eli Lilly and Company database. The study
selection criteria were 1) randomized, double-blind,
active-controlled, 2) duration of 24 to 28 weeks, and 3)
schizophrenia, schizophreniform disorder, or schizoaffec-
tive disorder. Four studies met these criteria. The 4 studies
included 1627 patients treated with olanzapine, risperi-
done, quetiapine, or ziprasidone. None of the studies
included a placebo arm. Patients were men and women
between the ages of 18 and 75. All protocols were
approved by the ethical review boards responsible for
individual study sites. All patients gave written, informed
consent prior to entering the study. The pooled analysis
included 1 trial comparing olanzapine and risperidone
[15], 1 trial comparing olanzapine and quetiapine [16],
and 2 trials comparing olanzapine and ziprasidone
[17,18]. Concomitant psychotropic medications were not
allowed during the studies with the exception of limited
benzodiazepines/hypnotics, approved antiparkinsonian
medications, and in studies 2 and 4, antidepressants if a
patient had been on a stable dose for 30 days prior to
study enrollment and remained on a stable dose during
the study.
Study designs
Study 1 was a 28-week, multi-center study of olanzapine
(10–20 mg/day, n = 172) versus risperidone (4–12 mg/
day, n = 167) in inpatients and outpatients meeting diag-
nostic criteria for schizophrenia, schizophreniform disor-
der, or schizoaffective disorder according to the DSM-IV
[15]. Patients had an initial score on the Brief Psychiatric
Rating Scale (BPRS) of at least 42.
Study 2 was a 6-month, multicenter study comparing the
efficacy of olanzapine (10–20 mg/day, n = 171) with
quetiapine (300–700 mg/day, n = 175) in outpatients
meeting DSM-IV criteria for schizophrenia and schizoaf-
fective disorder who had poor functioning and prominent
negative symptoms [16]. Patients had a score ≤60 on the
Global Assessment of Functioning (GAF) and a score ≥4
on at least 3 or ≥5 on at least 2 of the 7 negative scale items
on the Positive and Negative Syndrome Scale (PANSS).
Study 3 was a multicenter, 28-week study of olanzapine
(10–20 mg/day, n = 277) and ziprasidone (80–160 mg/
day, n = 271) in inpatients or outpatients meeting DSM-BMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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IV criteria for schizophrenia [17]. Patients had an initial
score of at least 42 on the BPRS and a score ≥4 on 1 of the
PANSS positive items in addition to a Clinical Global
Impressions-Severity score ≥4.
Study 4 was a multicenter, 24-week, fixed-dose study of
olanzapine (10, 15, or 20 mg/day, n = 202) and ziprasi-
done (80, 120, or 160 mg/day, n = 192) in inpatients or
outpatients meeting DSM-IV criteria for schizophrenia or
schizoaffective disorder with concurrent depressive symp-
toms [18]. Patients had a score ≥16 on the Montgomery-
Åsberg Depression Rating Scale (MADRS) and ≥4 on Item
2 (reported sadness).
Assessments
The primary objective of the present analysis was to assess
the pattern and reasons for treatment discontinuation/
continuation by pooling the 4 studies and collapsing all
treatment groups. Clinical trial investigators in all 4 stud-
ies were required to record reason and date of discontinu-
ation when patients left the trial before completing the
study. A clinical report form with a checklist of potential
reasons for discontinuation was used. The reasons for dis-
continuation are as follows:1) Adverse Event (AE)-with the
event specified. 2) Entry Criteria Not Met-checked when a
patient had been inappropriately enrolled in the trial
based on specific entry criteria. 3) Lack of Efficacy (LOE)-
Patient Perception-the patient perception was that symp-
tom improvement was not adequate for continued use of
the randomized medication. 4) Lack of Efficacy (LOE)-Phy-
sician Perception-the physician perception was that symp-
tom improvement was not adequate for continued use of
the randomized medication. 5) Lack of Efficacy (LOE)-
Patient and Physician Perception.  6) Lost to Follow-up-a
patient did not come to a scheduled visit and subse-
quently was unable to be contacted by phone or mail. 7)
Noncompliance-patients intentionally missed all doses for
a number of consecutive days specified for each trial or
regularly took more than the prescribed amount of medi-
cation. 8) Personal Conflict-the patient's decision for a vari-
ety of personal reasons, such as work conflict, lack of
transportation, change of location, or unwillingness to fill
out questionnaires. 9) Physician Decision-physician
decided that a patient should be discontinued due to rea-
sons other than lack of efficacy or satisfactory response;
examples include investigator sites closing and patients
deemed unreliable. 10) Sponsor Decision-the sponsor, Eli
Lilly and Company, decided that a patient should be dis-
continued following consultation with the investigator
treating the patient. 11) Clinical Relapse-Study 2 Only-clin-
ical relapse was based on predefined criteria, including an
increase in the following positive symptoms of schizo-
phrenia: delusions, conceptual disorganization, halluci-
natory behavior, or suspiciousness as measured by
PANSS; an increase in self depreciation as measured by
the Calgary Depression Scale for Schizophrenia; or hospi-
talization for any psychiatric condition. 12) Satisfactory
Response-Study 1 and Study 2 Only.
For the present analysis, discontinuation due to lack of
efficacy based on either patient or physician perception
(reasons 3, 4, and 5) was grouped together and used as a
measure of discontinuation due to poor symptom
response to treatment (termed poor response). Discontin-
uation due to psychiatric adverse events (e.g., emergent
psychosis or depression) along with "Clinical Relapse"
(Study 2 only-reason 11) was used as a measure of discon-
tinuation due to symptom worsening. These 2 categoriza-
tions, poor response and symptom worsening, represent a
continuum of treatment inefficacy. In contrast, discontin-
uation due to non-psychiatric adverse events was consid-
ered discontinuation due to medication intolerability.
The psychopathology of schizophrenia was measured by
visitwise analysis of mean total scores on the PANSS [19].
The PANSS is a 30-item scale that was designed to capture
numerous symptoms of schizophrenia, including delu-
sions, grandiosity, blunted affect, poor attention, and
poor impulse control.
Statistical methods
The analyses in this research were conducted combining
all the treatment groups in the 4 clinical studies. The dif-
ferences in PANSS total scores between study completers
and discontinued patients were tested using Analysis of
Variance (ANOVA) with term for group (completed vs.
discontinued) at all timepoints that were common for all
studies (Weeks 2, 4, 6, 8, 16, 20, and 24). In addition,
PANSS total scores were also compared among compl-
eters and patients who discontinued due to various rea-
sons, such as poor response/symptom worsening,
intolerability to medication, and others using ANOVA
with term for group. Logistic regression analysis was
applied to test if early response predicts study completion
with the independent variable as change in PANSS total at
Week 2. A similar model was used with the predictor as a
categorical variable defined as an improvement of 20% or
greater in PANSS total from baseline to 2 weeks.
Data on treatment discontinuation due to poor response
(lack of efficacy) were further assessed to compare the
patient's role to the physician's role in the perception of
treatment ineffectiveness and subsequent discontinuing
medication. In order to emphasize patient attitude toward
treatment response and the role of the patient in the deci-
sion to discontinue treatment, patient perception was
based on discontinuation by patient perception of poor
response either alone or in consensus with physician per-
ception (reasons 3 and 5) for the purpose of the current
analyses. Physician perception was based on physicianBMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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perception alone (reason 4). It should be noted that
results regarding perception would differ if patients that
discontinued due to poor response based on the consen-
sus of both patient and physician perception were catego-
rized differently. Time to discontinuation due to poor
response was assessed by Kaplan-Meier estimators for
patient perception and physician perception. Clinical
response as measured by PANSS total scores were com-
pared between patient perception and physician percep-
tion at all available visits using ANOVA. For patients who
discontinued due to adverse events, the actual event was
identified for all but 6 patients. All statistical tests are
based on a 2-tailed significance level of .05.
Results
Table 1 summarizes the study sample at baseline across
the 4 studies with treatment groups combined. A majority
of patients were male (64.4%), Caucasian (53.3%), and
had a diagnosis of schizophrenia (78.5%). The patient
mean age was 39.5 ± 10.8 years, and the mean age of ill-
ness onset was 23.5 ± 8.3 years. The mean baseline PANSS
total score was 91.27 ± 19.72, and 49.8% of patients had
been hospitalized prior to the study.
Reasons for discontinuation
A majority of patients (53%; 866/1627) discontinued
early from these 4 studies. The reasons for discontinua-
tion are summarized in Figure 1. The most common rea-
son for early treatment discontinuation was poor
response/psychiatric symptom worsening (36%; 315/
866), which was 3 times the rate of patient discontinua-
tion due to medication intolerability (12%; 106/866). In
particular, poor response accounted for 19% (164/866) of
patient discontinuation, and symptom worsening
accounted for 17% (151/866). The most common psychi-
atric adverse events (symptom worsening) cited for treat-
ment discontinuation were psychosis (n = 35); suicide
ideation, attempts, or completion (n = 18); schizophre-
nia, schizoaffective, or schizophreniform disorder (n =
17); and depression (n = 12). The non-psychiatric adverse
events (medication intolerability) most frequently cited
for treatment discontinuation were sedation (n = 7), som-
nolence (n = 7), abnormal ECG (n = 6), vomiting (n = 5),
dizziness (n = 4), dystonia (n = 3), fatigue (n = 3), abnor-
mal liver function test (n = 3), and increased weight (n =
3). The rates of and reasons for discontinuation across the
4 studies were fairly consistent and are shown in Table 2.
Symptom response: Completers versus patients who 
discontinued
In order to objectively examine the association between
poor clinical outcome and treatment discontinuation
independently of the checklist used at patient departure,
PANSS total scores at each assessment were compared
between patients who completed the study and those who
Flowchart of early treatment discontinuation Figure 1
Flowchart of early treatment discontinuation. Values 
are the summary of reasons for discontinuation from all 4 
studies. Poor Response was based on "Lack of Efficacy." 
Symptom Worsening was based on "Psychiatric Adverse 
Events" and a priori protocol defined "Clinical Relapse" (Study 
2 only).
All Patients
1627
Completers
761 of 1627 (47%)
Discontinued
866 of 1627 (53%)
Poor Response
or Worsening
315 of 866 (36%)
Intolerability
to Medication
106 of 866 (12%)
Other Reasons
•Criteria Not Met (12%)
•Lost to Follow-up (12%)
•Noncompliance (2%)
•Personal Conflict (20%)
•Physician Decision (4%)
•Satisfactory Response (0.2%)
•Sponsor Decision (1%) Poor Response
164 of 866 (19%)
Symptom
Worsening
151 of 866 (17%)
Table 1: Patient and disease characteristics
Characteristic Study 1 (n = 339) Study 2 (n = 346) Study 3 (n = 548) Study 4 (n = 394) Total (N = 1627)
Age (mean ± SD) 36.21 ± 10.73 41.05 ± 9.58 39.10 ± 11.8 41.59 ± 9.74 39.53 ± 10.85
Sex (Male %) 220(64.9) 228(65.9) 352(64.2) 248(62.9) 1048(64.4)
Race (Caucasian %) 253(74.6) 179(51.7) 239(43.6) 197(50.0) 868(53.3)
Diagnosis (%)
Schizophrenia 277(81.7) 230(66.5) 548(100) 223(56.6) 1278(78.5)
Schizoaffective 52(15.3) 116(33.5) -- 171(43.4) 339(20.84)
Schizophreniform 10(2.9) -- -- -- 10(0.6)
Age of Onset Illness (yrs ± SD) 23.51 ± 7.48 23.36 ± 8.21 23.37 ± 8.27 23.71 ± 8.93 23.48 ± 8.26
PANSS Total (mean ± SD) 96.08 ± 16.55 84.83 ± 14.03 100.9 ± 20.18 79.35 ± 17.51 91.27 ± 19.72
Prior Hospitalization (%) 337(99.4) 180(52.0) 105(19.2) 189(48.0) 811(49.8)
Hospitalization Days (mean ± SD)* 23.12 ± 43.89 55.45 ± 77.13 16.10 ± 37.4 41.12 ± 44.10 33.58 ± 54.31
Illness Duration (yrs ± SD) 12.57 ± 9.75 17.68 ± 9.50 15.80 ± 11.63 17.84 ± 10.59 16.02 ± 10.75
* Mean hospitalization days for group of patients reporting prior hospitalization.BMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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discontinued early. There was no significant difference in
baseline PANSS total scores between the patients who
completed and those who discontinued treatment (91.4 ±
19.2 and 91.1 ± 20.2, respectively; p = .744). However, at
each timepoint after treatment had begun, patients who
completed the study had significantly lower PANSS total
scores than patients who discontinued prior to the end of
the study (p < .001, Figure 2). Although both groups
showed significant clinical improvement compared to
baseline (p < .001 at each timepoint), patients who dis-
continued early from the study appeared to have a slower
initial rate of improvement and less improvement overall
as compared to those patients who completed the study.
In view of these results, it was of interest to determine if
early response predicted study completion. Symptom
improvement from baseline to 2 weeks as measured by
mean change in PANSS total score was significantly pre-
dictive of study completion (regression coefficient esti-
mate 0.02, p < .001). Further, defining early response as a
20% or greater improvement in PANSS total score at 2
weeks, 28.9% of patients (431 of 1492 available at Week
2) met the criteria. Based on this criteria, early response
was associated with an approximately 80% greater likeli-
hood of completing the study (odds ratio 1.76, confi-
dence interval 1.4, 2.21, p < .0001).
PANSS total scores at each assessment were also compared
among completers and patients who discontinued treat-
ment early due to poor response/symptom worsening,
intolerability to medication, and "other," respectively.
"Other" reasons for discontinuation were the same as
those described in Figure 1 and as described in detail in
the Methods section. There was a cross-group significant
difference from Week 0 through Week 6 and also at Week
20 (p < .05; Figure 3). In contrast to patients who discon-
tinued due to poor response or symptom worsening,
patients who discontinued due to medication intolerabil-
ity showed improvement in PANSS total scores compara-
ble to study completers, suggesting that adverse events do
not interfere with symptom response but do prevent an
otherwise effective treatment.
The baseline characteristics of patients who discontinued
early due to poor response or symptom worsening are
described in Table 3. This group of patients reported prior
hospitalization significantly more frequently than all
other patients (56.8%; 179/315 vs. 48.2%; 632/1312; p =
.007). In addition, these patients were significantly more
often Caucasian when compared with all other patients
(64.4%; 203/315 vs. 50.7%; 665/1312; p < .001). Other
baseline characteristics were similar between patients who
discontinued due to poor response or symptom worsen-
ing and the rest of the study population.
Patient perception
Discontinuation due to poor response was further charac-
terized to determine whether the patient or physician con-
cluded that symptom response was not adequate for
medication continuation. In order to emphasize the role
of patients in the decision to discontinue, discontinuation
due to patient perception of poor response in the follow-
ing analyses was defined as discontinuation due to patient
perception of poor response (lack of efficacy) either alone
or in consensus with physician conclusion. Physician per-
ception was based on physician perception of poor
response alone. Patient perception accounted for 80%
Visitwise PANSS total scores between patients who com- pleted the study and those who discontinued early Figure 2
Visitwise PANSS total scores between patients who 
completed the study and those who discontinued 
early. Values are means across all treatments and studies. *p 
< .001 between group difference. Completers (Com), Dis-
continued (D/C).
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Table 2: Reasons for discontinuation by study
Reason for Discontinuation n (%) Study 1 (n = 339) Study 2 (n = 346) Study 3 (n = 548) Study 4 (n = 394) Total (N = 1627)
Overall Discontinuation 161(47.5) 190(54.9) 268(48.9) 247(62.7) 866(53.2)
Poor Response or Worsening 67(41.6) 78(41.0) 99(36.9) 71(28.7) 315(36.4)
Intolerability to Medication 19(11.8) 16(8.4) 31(11.6) 40(16.2) 106(12.2)
Other Reasons* 75(46.6) 96(50.5) 138(51.5) 136(55.1) 445(51.4)
*Other reasons for discontinuation included criteria not met, lost to follow-up, noncompliance, personal conflict, physician decision, satisfactory 
response, and sponsor decision.BMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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(132/164) of discontinuation of treatment due to poor
response (Table 4 and Figure 4A). In addition, the time to
discontinuation was much sooner when patient percep-
tion in comparison to physician perception of poor
response was the reason for discontinuation (Figure 4B).
However, when PANSS total scores were compared
between the groups that discontinued due to poor
response by patient perception and by physician percep-
tion, the clinical performance was similar between the 2
groups (Figure 4C; the only significant difference in
PANSS scores between the groups was at Week 4, p = .02).
Discussion
Premature treatment discontinuation was very common
in these 4 schizophrenia clinical trials. The most common
reason for early treatment discontinuation was poor
symptom response/psychiatric symptom worsening,
which was substantially more common than discontinua-
tion due to medication intolerability. Patients who dis-
continued early from the study due to poor response or
symptom worsening had a slower initial rate of improve-
ment and less improvement overall compared to those
patients who completed the study. In contrast, patients
who discontinued due to medication intolerability were
showing symptom improvement comparable to study
completers up until discontinuation. Discontinuation
due to poor response was overwhelmingly linked to
patient perception of response compared to physician
observation alone. Discontinuation due to patient percep-
tion of poor response appeared to occur particularly early
in the treatment course.
The substantial rate of premature discontinuation from
these studies likely reflects the great challenge of treat-
ment adherence in the clinical treatment of patients with
schizophrenia. Discontinuation by more than half of the
patients in these trials is within the broad range of previ-
ous reports of antipsychotic discontinuation (25%–75%)
and is in line with reports of medication adherence in nat-
uralistic settings [1-4]. Both the present study and other
analyses of clinical trials likely underestimate the true
incidence (and likely the associated burden) of antipsy-
chotic nonadherence in the long-term course of therapy
since the studies are time-limited, and treatment of schiz-
ophrenia is a life-long consideration. Studies of older typ-
ical antipsychotics indicate that about 75% of patients
discontinue their medication within 2 years [5].
Perhaps the most interesting and important result of our
analysis is that treatment discontinuation due to inade-
quate control of psychiatric symptoms appeared 3 times
as likely as discontinuation due to medication intolerabil-
ity. This was an unexpected finding of this systematic
study since adverse events are a commonly cited reason
Table 3: Baseline characteristics of patients who discontinued due to poor response or symptom worsening
Characteristic Study 1 (n = 67) Study 2 (n = 78) Study 3 (n = 99) Study 4 (n = 71) Total (N = 315)
Age (mean ± SD) 36.17 ± 11.14 39.56 ± 9.36 38.58 ± 11.95 41.77 ± 9.91 39.03 ± 10.84
Sex (Male %) 43(64.2) 57(73.1) 58(58.6) 53(74.6) 211(67.0)
Race (Caucasian %)* 54(80.6) 48(61.5) 53(53.5) 48(67.6) 203(64.4)
Diagnosis (%)
Schizophrenia 57(85.1) 54(69.2) 99(100) 39(54.9) 249(79.8)
Schizoaffective 8(11.9) 24(30.8) -- 32(45.1) 64(20.5)
Schizophreniform 2 (3.0) -- -- -- 2 (0.6)
Age of Onset Illness (yrs ± SD) 22.80 ± 6.69 21.63 ± 6.85 22.44 ± 7.62 22.63 ± 7.43 22.36 ± 7.18
PANSS Total (mean ± SD) 95.48 ± 15.31 86.60 ± 15.60 105.83 ± 22.04 82.01 ± 16.82 93.50 ± 20.35
Prior Hospitalization (%)* 65(97.0) 45(57.7) 27(27.3) 42(59.2) 179(56.8)
Hospitalization days (mean ± SD)† 35.75 ± 54.52 73.11 ± 113.67 24.96 ± 69.32 49.14 ± 50.12 46.66 ± 76.40
Illness Duration (yrs ± SD) 13.25 ± 10.47 17.93 ± 9.53 16.13 ± 12.02 19.13 ± 10.83 16.65 ± 10.99
*Significantly different from all other patients (prior hospitalization, p = .007; Caucasian race, p < .0001).
† Mean hospitalization days for group of patients reporting prior hospitalization.
Visitwise PANSS total scores between patients who com- pleted the study and those who discontinued early due to  various reasons Figure 3
Visitwise PANSS total scores between patients who 
completed the study and those who discontinued 
early due to various reasons. Values are means across all 
treatments and studies. *p < .05 between group difference. 
Completers (Com), Poor response/symptom worsening (PR/
W), Intolerability to Medication (IM).
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for medication nonadherence [5,9]. Clinician experience
with the older typical antipsychotics may be partially
responsible for the perception of medication intolerabil-
ity being a more common reason for antipsychotic treat-
ment discontinuation. Other studies of patient attitudes
toward antipsychotic treatment adherence suggest that
adverse events may be important for patient attitudes
toward antipsychotic adherence in particular with typical
antipsychotics [20]. The transition of treatment of
patients with schizophrenia and related disorders from
typical to atypical agents over the past 10–15 years may
have resulted in a decrease in the incidence of discontinu-
ation due to adverse events relative to poor efficacy.
The high rate of discontinuation in the present study is
consistent with the results of the large, 18-month CATIE
trial in which 74% of patients discontinued their assigned
antipsychotic medication [14]. Treatment discontinua-
Patient and physician perception of efficacy Figure 4
Patient and physician perception of efficacy. A. Discontinuation due to poor response by perception. Patient perception 
was based on discontinuation by patient perception of poor response either alone or in consensus with physician perception. 
Physician perception was based on physician conclusion alone. B. Time to discontinuation (D/C) due to poor response by per-
ception. C. Visitwise PANSS total scores between patients who discontinued early due to poor response by patient perception 
and those by physician perception. *p < .05. Physician perception (Phy per), Patient perception (Pt per).
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Table 4: Discontinuation due to poor response by patient and/or physician perception
Reason for Discontinuation Study 1 Study 2 Study 3 Study 4 Total
Poor Response by Patient Perception Either Alone or in Consensus With 
Physician n (%*)
40(76.9) 18(85.7) 46(80.7) 28(82.4) 132(80.5)
Poor Response by Patient Perception Alone n (%*) 11(21.2) 9(42.9) 25(43.9) 14(41.2) 59(36.0)
Poor Response by Patient and Physician Perception n (%*) 29(55.8) 9(42.9) 21(36.8) 14(41.2) 73(44.5)
Poor Response by Physician Perception n (%*) 12(23.1) 3(14.3) 11(19.3) 6(17.6) 32(19.5)
*Denominator is the total number of patients that discontinued due to poor symptom response.BMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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tion because of lack of efficacy (24%) was also more com-
mon in the CATIE trial than discontinuation because of
medication intolerability (15%), consistent with the stud-
ies reported here.
Using an objective rating scale (PANSS), patients who dis-
continued had less improvement compared to study com-
pleters, suggesting that this patient group has a real deficit
in medication response. However, even patients who dis-
continued achieved response to a certain extent, suggest-
ing that there is a critical level of response needed to keep
patients on treatment. Patients appeared to be especially
likely to give up on treatments that did not provide a rapid
therapeutic response, as a 20% early response resulted in
an approximately 80% greater likelihood of remaining on
therapy. Although the notion that a substantial delay in
antipsychotic response is common in the field of psychia-
try [21], Agid et al. [22] recently reported the results of a
meta-analysis of double-blind, controlled trials that sug-
gests antipsychotic response starts within the first week of
therapy and accumulates over time. In addition, antipsy-
chotic response within the first week of treatment has
been reported to predict response after 6 weeks, at least for
haloperidol [23]. The present study expands upon these
findings by suggesting that early response also predicts
treatment continuation. Therefore, patient perception of
efficacy early on in treatment may be a major contributor
to engagement in treatment and adherence to the treat-
ment plan.
One possible explanation for the inadequate treatment
response of patients who discontinued treatment early
due to poor response or symptom worsening may be that
they are intrinsically less responsive to treatment. For
some patients, treatment resistance may represent an
intrinsic part of the schizophrenic illness, at least with cur-
rent antipsychotic medications [24]. The current study
provides limited data to address this possibility. In sup-
port of this hypothesis, patients who discontinued treat-
ment early due to poor response or symptom worsening
reported prior hospitalization significantly more than all
other patients. Treatment-resistant patients often require
extensive periods of hospitalization, and older studies
commonly used frequent hospitalization as an indicator
of treatment resistance, although this may not be accurate
in all cases [25]. On the other hand, other baseline char-
acteristics that might be associated with treatment resist-
ance, such as duration of illness and baseline illness
severity, were similar between patients who discontinued
due to poor response or symptom worsening and the rest
of the study population. Standardized criteria for treat-
ment resistance have been more recently described
[26,27]. Further studies using defined criteria for treat-
ment resistance are needed to better determine if patients
who discontinue treatment due to poor response or symp-
tom worsening are truly treatment resistant. Alternatively,
these patients may discontinue early because of a subop-
timal early treatment response and perceived lack of effi-
cacy, and may possibly benefit from an early, active
clinician-initiated attempt to bolster engagement in order
to maintain treatment adherence.
Interestingly, patients who discontinued due to medica-
tion intolerability were showing symptom improvement
comparable to study completers prior to their discontinu-
ation. It should be noted that some of the adverse events
were not considered severe; nonetheless, they were costly
to patients by derailing patients from the potential benefit
of the treatment. Had these patients continued their treat-
ment to study completion, they would have likely had a
clinically successful treatment. Therefore, adverse events
should be viewed as a significant barrier to treatment effi-
cacy and must be addressed on an individual patient
basis.
Weight gain is a potential adverse event of atypical antip-
sychotic treatment that has been cited by patients as
highly distressing [28] and has been proposed to be a fac-
tor in medication nonadherence [3]. However, weight
gain has rarely been directly investigated as a factor in
medication discontinuation or adherence. In the present
studies, weight gain was infrequently reported as a reason
for discontinuation (3 patients; 0.2%). However, weight
gain in more naturalistic treatment settings may be a more
important factor in patient adherence to medication than
reported here for clinical trials. Consistent with this
notion, in the CATIE trial, which was designed to have
several "real-world" features in order to make the results
more generalizable, there was a higher rate of treatment
discontinuation due to weight gain than reported here
[14]. Four percent of all patients discontinued due to
weight gain or metabolic effects, although the incidence
of discontinuation due to weight gain or metabolic effects
was higher in olanzapine-treated patients (9%).
In addition to the deficit in treatment response as meas-
ured by PANSS scores, there was also a subjective compo-
nent to the poor response reported by some patients.
While patient perception of poor response was responsi-
ble for treatment discontinuation much more frequently
than physician perception of poor response, patients who
discontinued due to patient perception of poor response
and patients who discontinued due to physician percep-
tion of poor response had similar PANSS scores, high-
lighting a subjective aspect of patient perception of
treatment effectiveness. This suggests that patients are
aware of whether they are getting better and may not be as
willing as physicians to allow more time for symptom
improvement if they perceive early in treatment that their
symptom response is less than optimal. These results areBMC Medicine 2005, 3:21 http://www.biomedcentral.com/1741-7015/3/21
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consistent with the health belief model that suggests a
patient's likelihood of adhering to prescribed medication
is a product of an implicit and subjective assessment of
the relative costs and benefits of adherence in relation to
personal goals and constraints [3,9,11]. These results
highlight the importance of active engagement of the
patient early in treatment, with a clear understanding of
the patient's expectations and treatment goals.
A limitation of the present analysis is that the reasons for
discontinuation on the checklist used to categorize dis-
continuation in the 4 clinical trials may have not opti-
mally captured the primary reason for discontinuation in
all cases. For instance, a relatively high number of patients
discontinued due to "personal conflicts," which included
a variety of specific reasons and were not analyzed in this
study. Categorizing all of these reasons as personal con-
flicts may have prevented the identification of additional
barriers to medication adherence and may mask an under-
lying patient concern regarding efficacy, tolerability, or
novel reasons that caused patients to lack the motivation
to continue. Finally, discontinuation due to physician
perception of response may have been underrepresented
since physician versus patient perception was only cap-
tured in regards to poor symptom response and was not
assessed in regards to symptom worsening (psychiatric
adverse events). Although discontinuation due to psychi-
atric adverse events was ultimately a physician decision, it
cannot be concluded that patients did not play a role in
this decision. Therefore, discontinuation due to symptom
worsening was not considered in the analysis of discon-
tinuation due to patient and physician perception of
response.
An additional limitation of the present study is that it is
based on clinical trials that may not reflect more natural-
istic patient treatment settings. Patients enrolled in the tri-
als were much more homogeneous than the patient
population seen in routine clinical care because of restric-
tions on patient enrollment. For instance, in the trials,
patients with alcohol and substance dependence were
excluded, and patients generally did not receive polyphar-
macy. In addition, clinical trials require that patients be
motivated to participate in the trial, so these patients may
have different implicit motivation and beliefs regarding
treatment than patients in other settings. As a conse-
quence, the rates of and reasons for discontinuation
reported in this study may not be generalizable to typical
outpatient settings. With these caveats, the systematic
investigation of reasons for early discontinuation in the
present study may still help to develop strategies to
improve patient engagement in long-term therapy.
Conclusion
In these studies, as in clinical management of patients
with schizophrenia, treatment discontinuation was strik-
ingly common. Poor response to treatment and worsen-
ing of underlying psychiatric symptoms, and to a lesser
extent, intolerability of medication were the most com-
mon reasons for treatment discontinuation. Both a real
inadequacy of treatment response, as well as patient per-
ception of failure to improve, contributed to early treat-
ment discontinuation. Improved treatment adherence in
schizophrenia can reduce the risk of relapse and its mor-
bid consequences, and perhaps promote higher function-
ing through better therapeutic engagement and by
building upon improvement. This study suggests that
adherence may be enhanced by effective symptom control
as objectively measured, and as subjectively perceived.
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